SCHEMBL16508090

SCHEMBL16508090

CCCCCCCCCCCCCCCC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)[C@@H](C)O)C(C)C

nearest known ligand 0.58

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ NPY4R P50391 13/20 0.58
▸ NPY5R Q15761 8/20 0.58
▸ NPY1R P25929 7/20 0.58
▸ NPY2R P49146 5/20 0.53
▸ RXFP1 Q9HBX9 1/20 0.48
▸ KISS1R Q969F8 1/20 0.44
▸ CTSL P07711 1/20 0.43
▸ PRSS1 P07477 1/20 0.43
▸ FURIN P09958 1/20 0.43
▸ GLP1R P43220 1/20 0.42
▸ GCGR P47871 1/20 0.42
▸ GIPR P48546 1/20 0.42
▸ MAPK8 P45983 1/20 0.40
▸ MAPK9 P45984 1/20 0.40
▸ MAPK10 P53779 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16508517 0.89 NPY4R (0.59) NPY4RNPY5RNPY1RNPY2RRXFP1
SCHEMBL16507926 0.88 NPY4R (0.53) NPY4RNPY5RNPY1RNPY2RRXFP1
SCHEMBL16508129 0.87 NPY4R (0.52) NPY4RNPY5RNPY1RNPY2RRXFP1
SCHEMBL16509117 0.86 NPY4R (0.57) NPY4RNPY5RNPY1RNPY2RRXFP1
SCHEMBL16507937 0.84 RXFP1 (0.55) NPY4RNPY5RNPY1RNPY2RRXFP1
SCHEMBL16507855 0.84 RXFP1 (0.55) NPY4RNPY5RNPY1RNPY2RRXFP1
SCHEMBL13363672 0.83 RXFP1 (0.54) NPY4RNPY5RNPY1RRXFP1PRSS1
SCHEMBL10168810 0.83 NPY5R (0.50) NPY4RNPY5RNPY1RNPY2RRXFP1
SCHEMBL16508061 0.83 RXFP1 (0.54) NPY4RNPY5RNPY1RRXFP1PRSS1
SCHEMBL3059817 0.83 NPY4R (0.69) NPY4RNPY5RNPY1RNPY2RKISS1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110294738-A1 PTHR1 RECEPTOR COMPOUNDS ANTHOR THERAPEUTICS, INC. 2011-12-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110294738-A1 PTHR1 RECEPTOR COMPOUNDS PTH1R, MC1R, CASR NPY4R 1387/4885NPY5R 1478/4885NPY1R 800/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback